Sandercock Colin - Net Worth and Insider Trading

Sandercock Colin Net Worth

The estimated net worth of Sandercock Colin is at least $29,798 dollars as of 2024-05-12. Sandercock Colin is the SVP, General Counsel and Sec of Cue Biopharma Inc and owns about 17,125 shares of Cue Biopharma Inc (CUE) stock worth over $29,798. Details can be seen in Sandercock Colin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sandercock Colin has not made any transactions after 2020-08-05 and currently still holds the listed stock(s).

Transaction Summary of Sandercock Colin

To

Sandercock Colin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sandercock Colin owns 1 companies in total, including Cue Biopharma Inc (CUE) .

Click here to see the complete history of Sandercock Colin’s form 4 insider trades.

Insider Ownership Summary of Sandercock Colin

Ticker Comapny Transaction Date Type of Owner
CUE Cue Biopharma Inc 2021-02-10 SVP & General Counsel and Sec

Sandercock Colin Latest Holdings Summary

Sandercock Colin currently owns a total of 1 stock. Sandercock Colin owns 17,125 shares of Cue Biopharma Inc (CUE) as of August 5, 2020, with a value of $29,798.

Latest Holdings of Sandercock Colin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CUE Cue Biopharma Inc 2020-08-05 17,125 1.74 29,798

Holding Weightings of Sandercock Colin


Sandercock Colin Form 4 Trading Tracker

According to the SEC Form 4 filings, Sandercock Colin has made a total of 5 transactions in Cue Biopharma Inc (CUE) over the past 5 years, including 2 buys and 3 sells. The most-recent trade in Cue Biopharma Inc is the sale of 13,274 shares on August 5, 2020, which brought Sandercock Colin around $265,480.

Insider Trading History of Sandercock Colin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sandercock Colin Trading Performance

GuruFocus tracks the stock performance after each of Sandercock Colin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sandercock Colin is -0.24%. GuruFocus also compares Sandercock Colin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sandercock Colin within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Sandercock Colin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Sandercock Colin

Average Return

Average return per transaction

Outperforming Transactions

2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -14.35
Relative Return to S&P 500(%) -18.03

Sandercock Colin Ownership Network

Ownership Network List of Sandercock Colin

No Data

Ownership Network Relation of Sandercock Colin


Sandercock Colin Owned Company Details

What does Cue Biopharma Inc do?

Who are the key executives at Cue Biopharma Inc?

Sandercock Colin is the SVP & General Counsel and Sec of Cue Biopharma Inc. Other key executives at Cue Biopharma Inc include President and CSO Anish Suri , director & CEO Daniel R Passeri , and Chief Medical Officer Matteo Levisetti .

Cue Biopharma Inc (CUE) Insider Trades Summary

Over the past 18 months, Sandercock Colin made no insider transaction in Cue Biopharma Inc (CUE). Other recent insider transactions involving Cue Biopharma Inc (CUE) include a net sale of 9,325 shares made by Peter A Kiener , a net purchase of 4,000 shares made by Anish Suri , and a net purchase of 3,000 shares made by Daniel R Passeri .

In summary, during the past 3 months, insiders sold 0 shares of Cue Biopharma Inc (CUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 9,325 shares of Cue Biopharma Inc (CUE) were sold and 7,000 shares were bought by its insiders, resulting in a net sale of 2,325 shares.

Cue Biopharma Inc (CUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cue Biopharma Inc Insider Transactions

No Available Data

Sandercock Colin Mailing Address

Above is the net worth, insider trading, and ownership report for Sandercock Colin. You might contact Sandercock Colin via mailing address: 40 Guest Street, Boston Ma 02135.

Discussions on Sandercock Colin

No discussions yet.